EVAg

Plasmid contains the entire genome of HIV-1 with a specific mutation in the protease gene, which has been described as a polymorphic mutation. It is unclear, whether it can confer drug resistance to specific HIV-1 PR inhibitors directly. It has been shown in cell culture that the presence of the 63P change leads to higher "replicative fitness" of the virus. The respective mutations have been reported in viruses from HIV-infected individuals on PR inhibitors with virologic therapy failure.

HIV-1 variant, infectious recombinant virus with specific mutations in the protease gene as indicated.

HIV-1 variant, infectious recombinant virus with specific mutations in the protease gene as indicated.

Influenza B Yamagata virus, B/Picardie/1392/2018 PA(I38T), epidemic isolate, baloxavir resistance, 2017-2018 season

Mutant of HIV-1, mutated "LLSGIV"-motif in gp41: LLSDIV, conferring resistance to Fuzeon

HIV-1 variant, infectious recombinant virus with specific mutations in the protease gene as indicated.

HIV-1 variant, infectious recombinant virus with specific mutations in the RT gene as indicated. These mutations confer resistance to specific HIV RT inhibitors and have been reported for emerging virus in vivo.

HIV-1 variant, infectious recombinant virus with specific mutations in the RT gene as indicated. These mutations confer resistance to specific HIV RT inhibitors and have been reported for emerging virus in vivo.

HIV-1 variant, infectious recombinant virus with specific mutations in the RT gene as indicated. These mutations confer resistance to specific HIV RT inhibitors and have been reported for emerging virus in vivo.

Plasmid contains the entire genome of HIV-1 with specific mutations in the reverse transcriptase gene, which can confer drug resistance to specific HIV-1 inhibitors. The respective mutations have been reported in viruses from HIV-infected individuals on reverse transcriptase inhibitors with virologic therapy failure.

Plasmid contains the entire genome of HIV-1 with specific mutations in the reverse transcriptase gene, which can confer drug resistance to specific HIV-1 inhibitors. The respective mutations have been reported in viruses from HIV-infected individuals on reverse transcriptase inhibitors with virologic therapy failure.

Plasmid contains the entire genome of HIV-1 with specific mutations in the reverse transcriptase gene, which can confer drug resistance to specific HIV-1 inhibitors. The respective mutations have been reported in viruses from HIV-infected individuals on reverse transcriptase inhibitors with virologic therapy failure.

HIV-1 recombinant, resistant to various HIV protease inhibitors

L90M mutation in the protease gene, which can confer drug resistance to specific HIV-1 PR inhibitors.

HIV-1 variant, infectious recombinant virus with specific mutations in the protease gene as indicated.

HIV-1 variant, infectious recombinant virus with specific mutations in the protease gene as indicated.

HIV-1 variant, infectious recombinant virus with specific mutations in the protease gene as indicated.

HIV-1 variant, infectious recombinant virus with specific mutations in the protease gene as indicated.

HIV-1 variant, infectious recombinant virus with specific mutations in the protease gene as indicated.

HIV-1 variant, infectious recombinant virus with specific mutations in the protease gene as indicated.

HIV-1 variant, infectious recombinant virus with specific mutations in the protease gene as indicated.

HIV-1 variant, infectious recombinant virus with specific mutations in the protease gene as indicated.

HIV-1 variant, infectious recombinant virus with specific mutations in the protease gene as indicated.